Upon antigen recognition, TRM cells rapidly reactivate through TCR–pMHC signaling, triggering MAPK/ERK and NF-κB pathways and releasing effector molecules such as IFN-γ and granzyme B, thereby exerting direct cytotoxicity against tumor cells. The gene discussed is NFKB1; the disease is neoplasm.